SCHAUMBURG, Ill.--(BUSINESS WIRE)--Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Eptifibatide for Injection in the United States as a therapeutic equivalent generic for Integrilin® for Injection (Eptifibatide) approved by the U.S.

伊利诺伊州绍姆堡（商业新闻短讯）--专注于提供关键注射药物的专业制药公司Avenacy今天宣布，它已在美国推出注射用依替巴肽，作为美国批准的注射用整合素®的治疗等效仿制药（依替巴肽）。

Food and Drug Administration. Eptifibatide for Injection is indicated for use in acute coronary syndrome (ACS) and percutaneous coronary intervention (PCI)..

食品和药物管理局。注射用依替巴肽适用于急性冠状动脉综合征（ACS）和经皮冠状动脉介入治疗（PCI）。。

Avenacy’s Eptifibatide for Injection is available as a 75 mg/100 mL single-dose vial. In line with Avenacy’s mission to champion patient safety and streamline patient care, Eptifibatide for Injection will feature the Company’s highly differentiated packaging and labeling to support accurate medication selection..

Avenacy的注射用依替巴肽可作为75 mg/100 mL单剂量小瓶提供。根据Avenacy维护患者安全和简化患者护理的使命，注射用依替巴肽将采用该公司高度分化的包装和标签，以支持准确的药物选择。。

Avenacy will begin shipping Eptifibatide for Injection to wholesale partners this week. The Company is supported by a global network of development and FDA-approved cGMP-certified contract manufacturing partners.

Avenacy将于本周开始向批发合作伙伴运送注射用依替巴肽。该公司得到了全球开发网络和FDA批准的cGMP认证合同制造合作伙伴的支持。

Eptifibatide for Injection had U.S. sales of approximately $8.3 million for the twelve months ending in June 2023.1

截至2023年6月的12个月内，注射用依替巴肽在美国的销售额约为830万美元

Approved Indications:

批准的适应症：

Acute Coronary Syndrome (ACS)

急性冠状动脉综合征（ACS）

Eptifibatide injection is indicated to decrease the rate of a combined endpoint of death or new myocardial infarction in patients with ACS (unstable angina/non-ST-elevation myocardial infarction), including patients who are to be managed medically and those undergoing percutaneous coronary intervention..

依替巴肽注射液可降低ACS（不稳定型心绞痛/非ST段抬高型心肌梗死）患者死亡或新发心肌梗死联合终点的发生率，包括接受药物治疗的患者和接受经皮冠状动脉介入治疗的患者。。

Percutaneous Coronary Intervention (PCI)

经皮冠状动脉介入治疗（PCI）

Eptifibatide injection is indicated to decrease the rate of a combined endpoint of death, new MI, or need for urgent intervention in patients undergoing PCI, including those undergoing intracoronary stenting.

依替巴肽注射可降低接受PCI的患者（包括接受冠状动脉内支架置入术的患者）的死亡，新发心肌梗死或需要紧急干预的综合终点发生率。

Please see link for Full Prescribing Information.

有关完整的处方信息，请参阅链接。

Integrilin® is a registered trademark of Merck.

Integridin® 是默克公司的注册商标。

1Source: IQVIA

1来源：IQVIA

About Avenacy

关于Avenacy

Avenacy is a U.S.-based specialty pharmaceutical company focused on supplying critical injectable medications used to treat patients in various medically supervised settings, from acute care hospitals to outpatient clinics and physician offices. Through a rigorous and optimized selection process, the Company is building out a pipeline of high-quality FDA approved injectable products in order to ensure a resilient portfolio that can meet the needs of today’s dynamic drug supply chain.

Avenacy是一家总部位于美国的专业制药公司，专注于提供用于在各种医疗监督环境中治疗患者的关键注射药物，从急诊医院到门诊诊所和医生办公室。通过严格和优化的选择过程，该公司正在建立一条高质量FDA批准的注射产品管道，以确保具有弹性的组合，能够满足当今动态药物供应链的需求。

With an experienced team, commitment to quality and reliability, and product offerings intended to facilitate safe and efficient patient care, Avenacy strives to be a trusted partner for essential medications..

凭借经验丰富的团队、对质量和可靠性的承诺以及旨在促进安全高效的患者护理的产品，Avenacy努力成为基本药物领域值得信赖的合作伙伴。。

Avenacy was launched in 2023 and is headquartered in Schaumburg, IL. For more information, please visit http://www.avenacy.com/.

Avenacy成立于2023年，总部位于伊利诺伊州绍姆堡。有关更多信息，请访问http://www.avenacy.com/.